Table 1.
The impact of SGLT2 inhibitors on diabetic cardiomyopathy.
| SGLT2 inhibitor | Study model | SGLT2 inhibitor mediated outcome | References |
|---|---|---|---|
| Empagliflozin (10 mg once daily) |
Subjects with T2DM and history of cardiovascular disease treated with empagliflozin for 3-months | • Decreased LVMI increased e′ |
Verma et al., 2016 |
| Empagliflozin (10 mg once daily) | Subjects with T2DM (20% with cardiovascular disease) treated with empagliflozin for 6-months | • Decreased LV end diastolic volume | Cohen et al., 2019 |
| Canagliflozin (100 mg once daily) | Subjects with T2DM (32% with cardiovascular disease) treated with canagliflozin for 3-months | • Decreased LVMI • Decreased E/e′ ratio |
Matsutani et al., 2018 |
| Dapagliflozin (5 mg once daily) | Subjects with T2DM and stable heart failure treated with dapagliflozin for 6-months | • Decreased LVMI • Decreased E/e′ ratio • Increased global Longitudinal strain |
Soga et al., 2018; Tanaka et al., 2020 |
| Tofogliflozin (20 mg once daily) | Subjects with T2DM without cardiovascular disease treated with tofogliflozin for ~8-months | • Decreased E/e′ ratio | Otagaki et al., 2019 |
| Empagliflozin (60 mg per kg of chow) | Female db/db mice treated with empagliflozin for 5-weeks | • Decreased E/e′ ratio • Increased e′/a′ ratio |
Habibi et al., 2017 |
| Empagliflozin (25 mg/kg intravenously) | ZDF rats treated acutely with empagliflozin | • Decreased IVRT • Increased mitral E/A ratio |
Pabel et al., 2018 |
| Empagliflozin (10 mg/kg/day) | Male db/db mice treated with empagliflozin for 8-weeks | • Decreased IVRT • Increased mitral E/A ratio |
Xue et al., 2019 |
| Empagliflozin (10 mg/kg/day) | Male Dahl salt-sensitive rats fed a high-salt diet and treated with empagliflozin for 2-weeks | • Decreased E/e′ ratio | Byrne et al., 2020 |
| Empagliflozin (10 mg/kg/day in the chow) | Male db/db mice treated with empagliflozin for 4-weeks | • No effect on the E/e′ ratio | Verma et al., 2018 |